Skip to main content

Table 1 Characteristics of included studies

From: Glucose–insulin–potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

Study No. of patients Age* Male(%)* Killip I (%)* Diabetes (%)* Glucose (%) Insulin (U/500 ml) Potassium (%) Infusion rate (ml/kg/h) Time from onset of symptom to treatment (h)* 24-h glucose (mmol/L)*
ECLA (1998)) 470 58.2/60.5 77/68.3 84.4/86.3 18.5/18 25 50 0.3 1.5 11.4/10.6 4.25/4.04
POL-GIK (1999) 954 62/60 70/67.2 94.1/97 6.5/6.1 10 32 0.3 42 ml/h 5 5.9/6.2
GIPS-I (2003) 940 59.9/60.8 73.7/79.3 89.5/92.7 10.5/10.6 20 7-11 0.3 3 2.75-2.78/2.75-2.82 7.7/8.1*
REVIAL (2004) 312 60.8/64.1 71.6/72.6 67.7/69.4 22.6/23.6 20 40 0.25 1.8 - -
CREATE-ECLA (2005) 20201 58.6/58.6 77.6/77.6 84.2/85.1 17.6/17.8 25 50 0.3 1.5 4.7/4.7¶ 8.6/7.5
Krljanac G (2005) 118 56.6/56.7 66.7/72.5 - 17/17 25 50 0.3 1 3.1/3.2 -
GIPS-II (2006) 889 61.8/61.2 73/74 100/100 9/10 20   0.3 2 - -
OASIS-6 (2007) 2748 61.5/62.1 73.1/71.7 - 14.9/14.0 25 50 0.3 1.5 - 8.5/7.5
IMMEDIATE (2012) 871 63.9/63.3 72.5/69.6 - 29.4/26.3 30 25 0.6 1.5 1.5/1.5 -
  1. ECLA = Estudios Cardiologicos Latinoamerica; POL-GIK = Polish-Glucose-Insulin-Potassium; GIPS-I = Glucose–insulin–potassium study-I; GIPS-II = Glucose–insulin–potassium study-II; REVIVAL = The Reevaluation of Intensified Venous Metabolic Support for Acute Infarct Size Limitation; OASIS-6 = Organization to Assess Strategies for Ischemic Syndromes; DIGAMI = the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction; HI-5 = The hyperglycemia: intensive insulin infusion in infarction; IMMEDIATE = the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial.
  2. *numerator/denominator indicates treatment group/control group.
  3. ¶median, Glucose (%) and potassium (%) mass concentration.